AstraZeneca's Farxiga Gets FDA OK to Reduce Hospitalization Risk in Type 2 Diabetes

Date : 10/21/2019 @ 11:53AM
Source : Dow Jones News
Stock : Astrazeneca Plc (AZN)
Quote : 7400.0  183.0 (2.54%) @ 1:39PM
Astrazeneca share price Chart

AstraZeneca's Farxiga Gets FDA OK to Reduce Hospitalization Risk in Type 2 Diabetes

Astrazeneca (LSE:AZN)
Historical Stock Chart

2 Months : From Oct 2019 to Dec 2019

Click Here for more Astrazeneca Charts.

By Colin Kellaher

 

AstraZeneca PLC (AZN, AZN.LN) on Monday said the U.S. Food and Drug Administration approved Farxiga to reduce the risk of hospitalization for heart failure in adults with type 2 diabetes.

The U.K. drug maker said Farxiga is the first sodium-glucose cotransporter 2 inhibitor approved in the U.S. to reduce the risk of hospitalization for heart failure in type 2 diabetes patients with established cardiovascular disease or multiple cardiovascular risk factors.

The FDA nod follows an update to Farxiga's marketing authorization in the EU in August. The drug is also under regulatory review in China, with a decision anticipated in the first half of 2020, AstraZeneca said.

 

Write to Colin Kellaher at colin.kellaher@wsj.com

 

(END) Dow Jones Newswires

October 21, 2019 07:38 ET (11:38 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:us D:20191216 13:54:50